Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Adverum Biotechnologies (ADVM) a New Strong Buy Stock

Albemarle

PagerDuty

Two growth stocks putting up great results and another that's out of favor but still delivering -- here's a trio you need to look at right now.

3 Top Growth Stocks to Buy Right Now: PagerDuty, Adverum & Albemarle

ArQule

Axsome Therapeutics

Provention Bio Inc

Zynerba Pharmaceuticals

These biotech stocks have at least quadrupled in just over six months this year.

5 Best Biotech Stocks of 2019 So Far

Adverum (ADVM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Adverum (ADVM) Jumps: Stock Rises 5.1%

uniQure

Voyager Therapeutics

Good news has a way of attracting suitors.

3 Biotechs That Have Doubled This Year (Acquisition Next?)

Diebold Nixdorf Inc

Enphase Energy

Roku

ZIOPHARM Oncology

Pfizer

Small-cap stocks have under-performed their large cap peers in 2019, but these 7 small-cap stocks have each more than tripled this year.

The 7 Top Small-Cap Stocks Of 2019

Adverum is a clinical-stage gene therapy biotech targeting ocular and rare diseases.

Adverum: Speculative Gene Therapy Play With In-House Capabilities Targeting The Validated And Attractive Ocular Space

Today, we look at a promising clinical stage gene therapy company, Adverum Biotechnologies.

Adverum Biotechnologies: A High Risk/High Reward Biotech Play In 2019

As of late, it has definitely been a great time to be an investor in Adverum Biotechnologies, Inc. (ADVM).

Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?

Iovance Biotherapeutics

MeiraGTx Holdings plc

Can these high-flying biotech stocks keep the momentum going?

3 Biotech Stocks That Soared Last Week: Are They Buys?

Adverum announced that the FDA has placed a clinical hold on one of its gene therapy products known as ADVM-022 to treat patients with wet age-related macular degeneration.

Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path

News for Adverum Biotechnologies Stock (ADVM)